| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 25 | 2019 | 881 | 3.660 |
Why?
|
| Geriatrics | 11 | 2019 | 94 | 2.380 |
Why?
|
| Geriatric Assessment | 7 | 2019 | 355 | 1.410 |
Why?
|
| Communicable Diseases | 5 | 2009 | 19 | 1.280 |
Why?
|
| Aged | 41 | 2019 | 9487 | 1.110 |
Why?
|
| HIV Infections | 5 | 2015 | 335 | 1.070 |
Why?
|
| Humans | 69 | 2019 | 29093 | 0.930 |
Why?
|
| Community-Acquired Infections | 5 | 2005 | 31 | 0.860 |
Why?
|
| Air Ambulances | 2 | 2016 | 10 | 0.840 |
Why?
|
| Biomedical Research | 7 | 2017 | 153 | 0.770 |
Why?
|
| Herpes Zoster | 3 | 2009 | 9 | 0.720 |
Why?
|
| Interleukin-23 | 4 | 2014 | 14 | 0.710 |
Why?
|
| Dendritic Cells | 2 | 2010 | 61 | 0.700 |
Why?
|
| Respiratory Tract Infections | 4 | 2012 | 41 | 0.700 |
Why?
|
| Fever of Unknown Origin | 2 | 2009 | 9 | 0.690 |
Why?
|
| Patient Care Planning | 1 | 2019 | 53 | 0.660 |
Why?
|
| Frail Elderly | 4 | 2019 | 65 | 0.650 |
Why?
|
| Kidney Diseases | 4 | 2014 | 239 | 0.650 |
Why?
|
| Disability Evaluation | 1 | 2019 | 211 | 0.640 |
Why?
|
| Vaccination | 2 | 2010 | 123 | 0.620 |
Why?
|
| Apolipoproteins | 3 | 2014 | 196 | 0.610 |
Why?
|
| Activities of Daily Living | 4 | 2009 | 238 | 0.600 |
Why?
|
| JC Virus | 2 | 2014 | 23 | 0.600 |
Why?
|
| Tumor Virus Infections | 2 | 2014 | 20 | 0.600 |
Why?
|
| Polyomavirus Infections | 2 | 2014 | 21 | 0.600 |
Why?
|
| Lipoproteins, HDL | 3 | 2014 | 247 | 0.600 |
Why?
|
| Pneumonia, Bacterial | 3 | 2005 | 31 | 0.580 |
Why?
|
| Thoracostomy | 1 | 2016 | 4 | 0.570 |
Why?
|
| Pneumothorax | 1 | 2016 | 8 | 0.570 |
Why?
|
| Research | 4 | 2010 | 72 | 0.550 |
Why?
|
| Internal Medicine | 4 | 2006 | 44 | 0.550 |
Why?
|
| Transcription Factors | 2 | 2009 | 172 | 0.530 |
Why?
|
| Comorbidity | 8 | 2015 | 540 | 0.520 |
Why?
|
| Inflammation | 2 | 2012 | 507 | 0.510 |
Why?
|
| Pneumonia | 2 | 2005 | 61 | 0.510 |
Why?
|
| Female | 28 | 2019 | 18164 | 0.480 |
Why?
|
| Aging, Premature | 1 | 2013 | 3 | 0.480 |
Why?
|
| Cytokines | 2 | 2012 | 243 | 0.480 |
Why?
|
| Aged, 80 and over | 12 | 2019 | 3717 | 0.480 |
Why?
|
| Anti-Infective Agents | 3 | 2015 | 43 | 0.480 |
Why?
|
| Male | 26 | 2019 | 17807 | 0.470 |
Why?
|
| Physical Fitness | 2 | 2012 | 119 | 0.470 |
Why?
|
| United States | 14 | 2017 | 3630 | 0.470 |
Why?
|
| T-Lymphocytes | 3 | 2013 | 114 | 0.460 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 250 | 0.460 |
Why?
|
| Chronic Disease | 6 | 2016 | 369 | 0.460 |
Why?
|
| Middle Aged | 17 | 2016 | 10829 | 0.460 |
Why?
|
| Diabetes Complications | 1 | 2014 | 171 | 0.450 |
Why?
|
| Bacterial Translocation | 1 | 2012 | 8 | 0.440 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 10 | 0.440 |
Why?
|
| Membrane Glycoproteins | 2 | 2012 | 97 | 0.440 |
Why?
|
| Models, Immunological | 1 | 2012 | 10 | 0.430 |
Why?
|
| Panax | 1 | 2012 | 8 | 0.420 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 17 | 0.420 |
Why?
|
| Health Services Research | 1 | 2012 | 78 | 0.420 |
Why?
|
| Virus Diseases | 2 | 2012 | 19 | 0.410 |
Why?
|
| Medicine | 4 | 2017 | 30 | 0.410 |
Why?
|
| Carrier Proteins | 1 | 2012 | 131 | 0.410 |
Why?
|
| B-Lymphocytes | 3 | 2010 | 69 | 0.410 |
Why?
|
| Plant Extracts | 1 | 2012 | 60 | 0.400 |
Why?
|
| Models, Biological | 1 | 2013 | 373 | 0.400 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2010 | 6 | 0.390 |
Why?
|
| Health Priorities | 1 | 2010 | 14 | 0.380 |
Why?
|
| Adult | 15 | 2016 | 8420 | 0.380 |
Why?
|
| Clostridium difficile | 3 | 2016 | 12 | 0.380 |
Why?
|
| Dinoprostone | 1 | 2010 | 37 | 0.380 |
Why?
|
| Evidence-Based Practice | 1 | 2010 | 25 | 0.370 |
Why?
|
| African Americans | 2 | 2014 | 1373 | 0.360 |
Why?
|
| Interleukin-12 | 3 | 2014 | 26 | 0.360 |
Why?
|
| Acute Disease | 2 | 2012 | 239 | 0.360 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2009 | 4 | 0.350 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2009 | 10 | 0.350 |
Why?
|
| Transportation of Patients | 2 | 2009 | 20 | 0.350 |
Why?
|
| Histones | 1 | 2009 | 49 | 0.350 |
Why?
|
| Homes for the Aged | 1 | 2009 | 19 | 0.340 |
Why?
|
| Patient Care Management | 1 | 2009 | 17 | 0.340 |
Why?
|
| Nursing Homes | 1 | 2009 | 42 | 0.340 |
Why?
|
| Antibodies, Bacterial | 2 | 2013 | 31 | 0.340 |
Why?
|
| Cross Infection | 1 | 2009 | 46 | 0.340 |
Why?
|
| Risk Factors | 10 | 2016 | 3531 | 0.340 |
Why?
|
| Cytomegalovirus Infections | 4 | 2013 | 25 | 0.320 |
Why?
|
| Herpesvirus Vaccines | 1 | 2007 | 1 | 0.320 |
Why?
|
| Herpesvirus 3, Human | 1 | 2007 | 3 | 0.320 |
Why?
|
| Animals | 13 | 2015 | 7297 | 0.320 |
Why?
|
| Brucella abortus | 1 | 2007 | 2 | 0.310 |
Why?
|
| Brucellosis | 1 | 2007 | 5 | 0.310 |
Why?
|
| Viral Vaccines | 1 | 2007 | 13 | 0.310 |
Why?
|
| Home Infusion Therapy | 1 | 2007 | 1 | 0.310 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 1013 | 0.310 |
Why?
|
| Home Care Services, Hospital-Based | 1 | 2007 | 3 | 0.310 |
Why?
|
| Immunization | 1 | 2007 | 28 | 0.310 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2009 | 154 | 0.300 |
Why?
|
| Neuralgia | 1 | 2007 | 48 | 0.300 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 231 | 0.300 |
Why?
|
| Congresses as Topic | 4 | 2019 | 37 | 0.290 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 481 | 0.290 |
Why?
|
| Specialization | 3 | 2019 | 30 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2007 | 83 | 0.280 |
Why?
|
| Apoptosis | 4 | 2006 | 337 | 0.280 |
Why?
|
| Antigens, Surface | 1 | 2005 | 19 | 0.280 |
Why?
|
| Individuality | 1 | 2005 | 5 | 0.280 |
Why?
|
| Mice | 7 | 2015 | 2368 | 0.270 |
Why?
|
| Prognosis | 6 | 2013 | 1362 | 0.270 |
Why?
|
| Hospitals, University | 1 | 2005 | 23 | 0.270 |
Why?
|
| Spleen | 1 | 2005 | 82 | 0.270 |
Why?
|
| Immunologic Factors | 1 | 2005 | 48 | 0.260 |
Why?
|
| Skin Ulcer | 2 | 2015 | 10 | 0.260 |
Why?
|
| Clostridium Infections | 2 | 2016 | 9 | 0.260 |
Why?
|
| Malnutrition | 1 | 2005 | 17 | 0.260 |
Why?
|
| Trauma Centers | 1 | 2005 | 84 | 0.260 |
Why?
|
| Influenza Vaccines | 3 | 2014 | 78 | 0.260 |
Why?
|
| Long-Term Care | 4 | 2014 | 21 | 0.250 |
Why?
|
| Health Status Indicators | 1 | 2004 | 67 | 0.250 |
Why?
|
| Prostaglandin D2 | 2 | 2005 | 4 | 0.240 |
Why?
|
| Hepatitis C, Chronic | 2 | 2015 | 77 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 160 | 0.240 |
Why?
|
| Cognition | 2 | 2005 | 526 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 3 | 2013 | 285 | 0.240 |
Why?
|
| Pesticides | 1 | 2016 | 189 | 0.230 |
Why?
|
| alpha-Tocopherol | 1 | 2002 | 1 | 0.230 |
Why?
|
| Occupational Exposure | 1 | 2016 | 224 | 0.230 |
Why?
|
| Mucous Membrane | 1 | 2002 | 20 | 0.220 |
Why?
|
| Vitamin A | 1 | 2002 | 19 | 0.220 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 14 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 235 | 0.220 |
Why?
|
| Awards and Prizes | 1 | 2002 | 11 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 281 | 0.220 |
Why?
|
| Incidence | 4 | 2012 | 1119 | 0.220 |
Why?
|
| Hematologic Neoplasms | 1 | 2002 | 28 | 0.210 |
Why?
|
| Academic Medical Centers | 1 | 2002 | 150 | 0.200 |
Why?
|
| Young Adult | 4 | 2016 | 2402 | 0.200 |
Why?
|
| Age Factors | 6 | 2015 | 1108 | 0.200 |
Why?
|
| Stem Cell Transplantation | 1 | 2002 | 203 | 0.190 |
Why?
|
| Intubation, Intratracheal | 2 | 2019 | 70 | 0.190 |
Why?
|
| Health Services Needs and Demand | 2 | 2012 | 66 | 0.190 |
Why?
|
| Education, Medical | 2 | 2019 | 67 | 0.190 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 162 | 0.190 |
Why?
|
| Treatment Outcome | 6 | 2016 | 3099 | 0.190 |
Why?
|
| Evidence-Based Medicine | 2 | 2014 | 207 | 0.180 |
Why?
|
| Linear Models | 4 | 2015 | 426 | 0.180 |
Why?
|
| Staff Development | 1 | 2019 | 13 | 0.180 |
Why?
|
| Breast Neoplasms | 2 | 2002 | 666 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 3 | 2013 | 711 | 0.180 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2019 | 6 | 0.180 |
Why?
|
| Hispanic Americans | 1 | 2016 | 904 | 0.180 |
Why?
|
| Teaching | 1 | 2019 | 55 | 0.180 |
Why?
|
| Up-Regulation | 2 | 2010 | 183 | 0.170 |
Why?
|
| Mentors | 1 | 2019 | 29 | 0.170 |
Why?
|
| Faculty, Medical | 1 | 2019 | 69 | 0.170 |
Why?
|
| Age Distribution | 3 | 2013 | 198 | 0.170 |
Why?
|
| Leadership | 1 | 2019 | 34 | 0.170 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 60 | 0.170 |
Why?
|
| Immunity, Innate | 2 | 2016 | 64 | 0.160 |
Why?
|
| Adolescent | 4 | 2016 | 3254 | 0.160 |
Why?
|
| Mobility Limitation | 1 | 2019 | 187 | 0.150 |
Why?
|
| PPAR gamma | 2 | 2015 | 45 | 0.150 |
Why?
|
| Safety | 2 | 2009 | 72 | 0.150 |
Why?
|
| Career Mobility | 1 | 2017 | 14 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 863 | 0.150 |
Why?
|
| Wound Healing | 2 | 2015 | 182 | 0.150 |
Why?
|
| Mice, Inbred DBA | 2 | 2007 | 36 | 0.150 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2016 | 16 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 2 | 2012 | 518 | 0.150 |
Why?
|
| Empyema | 1 | 2016 | 1 | 0.140 |
Why?
|
| Chest Tubes | 1 | 2016 | 6 | 0.140 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2016 | 23 | 0.140 |
Why?
|
| Arachidonic Acid | 2 | 2006 | 35 | 0.140 |
Why?
|
| Lymphocyte Count | 2 | 2005 | 23 | 0.140 |
Why?
|
| Cell Survival | 4 | 2010 | 272 | 0.140 |
Why?
|
| Morbidity | 2 | 2007 | 91 | 0.140 |
Why?
|
| Forecasting | 3 | 2015 | 133 | 0.130 |
Why?
|
| PPAR alpha | 1 | 2015 | 29 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 3 | 2014 | 160 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 74 | 0.130 |
Why?
|
| Aviation | 1 | 2015 | 1 | 0.130 |
Why?
|
| Electric Stimulation Therapy | 1 | 2015 | 18 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2005 | 91 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2016 | 3111 | 0.130 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2015 | 43 | 0.120 |
Why?
|
| Adaptive Immunity | 2 | 2013 | 14 | 0.120 |
Why?
|
| Double-Blind Method | 2 | 2013 | 501 | 0.120 |
Why?
|
| Digestive System | 1 | 2013 | 3 | 0.120 |
Why?
|
| Hyperglycemia | 1 | 2014 | 82 | 0.120 |
Why?
|
| Influenzavirus A | 1 | 2013 | 1 | 0.120 |
Why?
|
| Population Groups | 1 | 2013 | 7 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 637 | 0.120 |
Why?
|
| Virion | 1 | 2013 | 7 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2014 | 28 | 0.120 |
Why?
|
| Adjuvants, Immunologic | 1 | 2014 | 51 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2015 | 514 | 0.120 |
Why?
|
| Patient Care | 1 | 2014 | 33 | 0.120 |
Why?
|
| Mass Vaccination | 1 | 2013 | 7 | 0.120 |
Why?
|
| Eye | 1 | 2013 | 15 | 0.120 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2013 | 12 | 0.120 |
Why?
|
| Societies, Medical | 3 | 2017 | 149 | 0.120 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2013 | 18 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 25 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 366 | 0.120 |
Why?
|
| Hepatitis B Vaccines | 1 | 2013 | 10 | 0.110 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 7 | 0.110 |
Why?
|
| Hepatitis B | 1 | 2013 | 15 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2006 | 249 | 0.110 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 9 | 0.110 |
Why?
|
| Glioma | 1 | 2014 | 133 | 0.110 |
Why?
|
| Polypharmacy | 1 | 2012 | 20 | 0.110 |
Why?
|
| Program Development | 2 | 2019 | 85 | 0.110 |
Why?
|
| Hand Strength | 1 | 2012 | 85 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 1356 | 0.110 |
Why?
|
| Osteoarthritis | 1 | 2013 | 74 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2012 | 66 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2013 | 122 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 980 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2012 | 50 | 0.100 |
Why?
|
| Bone Marrow Cells | 2 | 2010 | 114 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 101 | 0.100 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2012 | 104 | 0.100 |
Why?
|
| Gait | 1 | 2012 | 115 | 0.100 |
Why?
|
| Exercise Test | 1 | 2012 | 194 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2014 | 466 | 0.100 |
Why?
|
| Survival Rate | 2 | 2005 | 795 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2013 | 256 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2016 | 670 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 532 | 0.100 |
Why?
|
| African Continental Ancestry Group | 1 | 2012 | 350 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 374 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2012 | 251 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 2 | 2009 | 212 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2013 | 47 | 0.100 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2010 | 5 | 0.100 |
Why?
|
| Flow Cytometry | 3 | 2005 | 171 | 0.100 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2010 | 4 | 0.100 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2010 | 11 | 0.100 |
Why?
|
| Shoulder Joint | 1 | 2013 | 123 | 0.100 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 5 | 0.090 |
Why?
|
| Creatinine | 1 | 2011 | 174 | 0.090 |
Why?
|
| Motor Activity | 1 | 2013 | 310 | 0.090 |
Why?
|
| Antigen-Presenting Cells | 1 | 2010 | 6 | 0.090 |
Why?
|
| Neoplasms | 1 | 2016 | 610 | 0.090 |
Why?
|
| Telomere | 1 | 2010 | 10 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2013 | 666 | 0.090 |
Why?
|
| Immunization Schedule | 1 | 2010 | 24 | 0.090 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 41 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 66 | 0.090 |
Why?
|
| Syndrome | 2 | 2013 | 66 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2009 | 1 | 0.090 |
Why?
|
| Nurses | 1 | 2009 | 14 | 0.090 |
Why?
|
| Chromatin | 1 | 2009 | 19 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2010 | 225 | 0.090 |
Why?
|
| Tissue Engineering | 1 | 2015 | 608 | 0.090 |
Why?
|
| Nursing Diagnosis | 1 | 2009 | 2 | 0.090 |
Why?
|
| Triazenes | 2 | 2006 | 4 | 0.090 |
Why?
|
| Body Temperature | 1 | 2009 | 22 | 0.090 |
Why?
|
| Time Factors | 3 | 2004 | 2001 | 0.090 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2009 | 23 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 152 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2009 | 35 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 53 | 0.080 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 17 | 0.080 |
Why?
|
| Physical Examination | 1 | 2009 | 82 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2015 | 454 | 0.080 |
Why?
|
| Immunity | 1 | 2008 | 19 | 0.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2008 | 28 | 0.080 |
Why?
|
| HIV-1 | 1 | 2008 | 42 | 0.080 |
Why?
|
| Physician Assistants | 1 | 2009 | 41 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2008 | 61 | 0.080 |
Why?
|
| Aspergillosis | 1 | 2007 | 4 | 0.080 |
Why?
|
| Lymphocyte Depletion | 1 | 2007 | 14 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 494 | 0.080 |
Why?
|
| Opportunistic Infections | 1 | 2007 | 9 | 0.080 |
Why?
|
| Health Services for the Aged | 1 | 2007 | 25 | 0.080 |
Why?
|
| Th1 Cells | 1 | 2007 | 18 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 1 | 2007 | 65 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2007 | 47 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 85 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 104 | 0.070 |
Why?
|
| Education, Medical, Continuing | 2 | 2006 | 45 | 0.070 |
Why?
|
| Liver | 3 | 2015 | 464 | 0.070 |
Why?
|
| North Carolina | 2 | 2016 | 1423 | 0.070 |
Why?
|
| Antigens, CD | 2 | 2004 | 100 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2012 | 1305 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2006 | 175 | 0.070 |
Why?
|
| Transcription, Genetic | 2 | 2006 | 136 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2005 | 20 | 0.070 |
Why?
|
| Receptors, IgG | 1 | 2005 | 7 | 0.070 |
Why?
|
| Drug Resistance, Microbial | 1 | 2005 | 11 | 0.070 |
Why?
|
| Nitrobenzenes | 1 | 2005 | 10 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2009 | 268 | 0.070 |
Why?
|
| Receptors, Eicosanoid | 1 | 2005 | 3 | 0.070 |
Why?
|
| Immunologic Memory | 1 | 2005 | 31 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2006 | 63 | 0.070 |
Why?
|
| Arachidonic Acids | 1 | 2005 | 23 | 0.070 |
Why?
|
| Chronology as Topic | 1 | 2005 | 1 | 0.070 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2005 | 3 | 0.070 |
Why?
|
| Clinical Competence | 2 | 2005 | 307 | 0.070 |
Why?
|
| Organophosphorus Compounds | 1 | 2005 | 35 | 0.070 |
Why?
|
| Emergency Medical Technicians | 1 | 2005 | 11 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2005 | 106 | 0.070 |
Why?
|
| Tennessee | 1 | 2005 | 97 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2005 | 65 | 0.070 |
Why?
|
| Imidazoles | 1 | 2005 | 104 | 0.070 |
Why?
|
| Neutrophils | 1 | 2005 | 102 | 0.060 |
Why?
|
| Research Design | 2 | 2006 | 286 | 0.060 |
Why?
|
| Nutrition Assessment | 1 | 2005 | 54 | 0.060 |
Why?
|
| Disease Susceptibility | 2 | 2016 | 53 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2005 | 186 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2004 | 20 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 273 | 0.060 |
Why?
|
| Phenotype | 3 | 2013 | 629 | 0.060 |
Why?
|
| Hematopoiesis | 1 | 2004 | 34 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2005 | 126 | 0.060 |
Why?
|
| Familial Mediterranean Fever | 1 | 2003 | 2 | 0.060 |
Why?
|
| Genetic Heterogeneity | 1 | 2003 | 13 | 0.060 |
Why?
|
| Periodicity | 1 | 2003 | 10 | 0.060 |
Why?
|
| Population Dynamics | 1 | 2003 | 5 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 45 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 95 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2016 | 859 | 0.060 |
Why?
|
| Retirement | 1 | 2003 | 11 | 0.060 |
Why?
|
| Biopsy | 2 | 2015 | 241 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 726 | 0.060 |
Why?
|
| Tocopherols | 1 | 2002 | 3 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2005 | 573 | 0.060 |
Why?
|
| Mortality | 1 | 2004 | 109 | 0.060 |
Why?
|
| Training Support | 1 | 2002 | 5 | 0.060 |
Why?
|
| Response Elements | 1 | 2002 | 16 | 0.060 |
Why?
|
| Research Support as Topic | 1 | 2002 | 25 | 0.060 |
Why?
|
| Fluoroquinolones | 1 | 2002 | 10 | 0.060 |
Why?
|
| Protein Transport | 1 | 2002 | 74 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 82 | 0.060 |
Why?
|
| Leukemia | 1 | 2002 | 36 | 0.060 |
Why?
|
| Demography | 1 | 2002 | 104 | 0.050 |
Why?
|
| Lymphoma | 1 | 2002 | 36 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 158 | 0.050 |
Why?
|
| Developing Countries | 1 | 2002 | 43 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2002 | 11 | 0.050 |
Why?
|
| Health Status | 1 | 2004 | 368 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 293 | 0.050 |
Why?
|
| Child | 1 | 2008 | 2219 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2002 | 105 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2003 | 181 | 0.050 |
Why?
|
| Albuminuria | 2 | 2013 | 176 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 287 | 0.050 |
Why?
|
| Depression | 1 | 2004 | 380 | 0.050 |
Why?
|
| Data Collection | 1 | 2002 | 163 | 0.050 |
Why?
|
| Educational Status | 1 | 2002 | 164 | 0.050 |
Why?
|
| Physicians | 1 | 2003 | 134 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 493 | 0.050 |
Why?
|
| Disease Progression | 2 | 2015 | 572 | 0.050 |
Why?
|
| Video Recording | 1 | 2019 | 52 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2013 | 836 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 96 | 0.040 |
Why?
|
| Pedigree | 2 | 2012 | 133 | 0.040 |
Why?
|
| Curriculum | 1 | 2019 | 196 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 30 | 0.030 |
Why?
|
| Caspases | 2 | 2005 | 31 | 0.030 |
Why?
|
| Caspase 3 | 2 | 2005 | 30 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 75 | 0.030 |
Why?
|
| Reference Values | 1 | 2015 | 224 | 0.030 |
Why?
|
| Canada | 1 | 2015 | 48 | 0.030 |
Why?
|
| Tracheostomy | 1 | 2015 | 28 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2015 | 130 | 0.030 |
Why?
|
| Immunity, Mucosal | 1 | 2014 | 5 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 2014 | 9 | 0.030 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2014 | 22 | 0.030 |
Why?
|
| Influenza B virus | 1 | 2014 | 20 | 0.030 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2014 | 20 | 0.030 |
Why?
|
| Vaccines, Inactivated | 1 | 2014 | 37 | 0.030 |
Why?
|
| Viral Load | 1 | 2014 | 64 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 55 | 0.030 |
Why?
|
| Immunity, Active | 1 | 2013 | 1 | 0.030 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2013 | 10 | 0.030 |
Why?
|
| Transgenes | 1 | 2013 | 45 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2013 | 12 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2013 | 30 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 274 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2013 | 1 | 0.030 |
Why?
|
| Cystatin C | 1 | 2013 | 28 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 52 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2005 | 680 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2013 | 39 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2013 | 14 | 0.030 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2013 | 6 | 0.030 |
Why?
|
| Jaundice | 1 | 2013 | 4 | 0.030 |
Why?
|
| Gene Expression | 2 | 2005 | 332 | 0.030 |
Why?
|
| Cholestasis | 1 | 2013 | 18 | 0.030 |
Why?
|
| Disease Management | 1 | 2014 | 114 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2013 | 21 | 0.030 |
Why?
|
| Isotonic Contraction | 1 | 2012 | 8 | 0.030 |
Why?
|
| Myofibrils | 1 | 2012 | 10 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 59 | 0.030 |
Why?
|
| Length of Stay | 1 | 2014 | 292 | 0.030 |
Why?
|
| Heredity | 1 | 2012 | 12 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2014 | 469 | 0.030 |
Why?
|
| Physical Conditioning, Animal | 1 | 2012 | 32 | 0.030 |
Why?
|
| Models, Animal | 1 | 2013 | 160 | 0.030 |
Why?
|
| Lung | 1 | 2014 | 233 | 0.030 |
Why?
|
| Muscular Atrophy | 1 | 2012 | 67 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2012 | 225 | 0.030 |
Why?
|
| Myosin Heavy Chains | 1 | 2012 | 86 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2013 | 177 | 0.030 |
Why?
|
| Monocytes | 1 | 2013 | 119 | 0.030 |
Why?
|
| Hospitalization | 1 | 2014 | 417 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 896 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 816 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 2019 | 0.020 |
Why?
|
| Kidney | 1 | 2012 | 485 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 871 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2007 | 34 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2007 | 18 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 113 | 0.020 |
Why?
|
| Methotrexate | 1 | 2007 | 60 | 0.020 |
Why?
|
| Immunosuppression | 1 | 2007 | 80 | 0.020 |
Why?
|
| Certification | 1 | 2006 | 24 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 440 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2006 | 11 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2006 | 6 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 18 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 167 | 0.020 |
Why?
|
| Coenzyme A Ligases | 1 | 2005 | 2 | 0.020 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2005 | 3 | 0.020 |
Why?
|
| Acyltransferases | 1 | 2005 | 16 | 0.020 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2005 | 2 | 0.020 |
Why?
|
| Anilides | 1 | 2005 | 7 | 0.020 |
Why?
|
| Pertussis Toxin | 1 | 2005 | 16 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2006 | 249 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 9 | 0.020 |
Why?
|
| Mitosis | 1 | 2005 | 22 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2005 | 67 | 0.020 |
Why?
|
| Hela Cells | 1 | 2005 | 78 | 0.020 |
Why?
|
| Binding Sites | 1 | 2005 | 125 | 0.020 |
Why?
|
| Protein Binding | 1 | 2005 | 199 | 0.020 |
Why?
|
| Transfection | 1 | 2005 | 192 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2004 | 22 | 0.020 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2004 | 4 | 0.020 |
Why?
|
| Cell Line | 1 | 2005 | 449 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 54 | 0.020 |
Why?
|
| Virus Replication | 1 | 2004 | 47 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 172 | 0.010 |
Why?
|
| Founder Effect | 1 | 2003 | 4 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2003 | 14 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 205 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2003 | 25 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 1687 | 0.010 |
Why?
|
| Family Health | 1 | 2003 | 78 | 0.010 |
Why?
|
| Haplotypes | 1 | 2003 | 220 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 165 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2004 | 167 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 150 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2002 | 169 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 246 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 641 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 2108 | 0.010 |
Why?
|